Every 8-K that Embecta Corp (EMBC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EMBC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EMBC filings page.
Embecta Corp. reported third quarter fiscal 2026 revenue of $271.7 million, down 8.1% year-over-year, with U.S. revenue down 24.6% and International up 11.5%. Gross margin declined to 56.4% from 66.7%. Net income was $21.1 million (diluted EPS $0.36) versus $45.5 million ($0.78) a year earlier. Adjusted EBITDA was $85.7 million with a 31.5% margin, and adjusted EPS was $0.56, both below the prior-year quarter.
For the nine months ended June 30, 2026, revenue was $754.7 million, down 7.6%, with adjusted net income of $91.0 million and adjusted EPS of $1.53. The company completed the Owen Mumford acquisition, contributing $13.8 million of revenue year-to-date, and is expanding GLP‑1 co-packaging launches globally. Embecta ended the quarter with $218.2 million in cash and equivalents and restricted cash and $1.469 billion of debt principal outstanding, after borrowing $180 million and repaying about $53 million. It declared a quarterly dividend of $0.01 per share and reaffirmed fiscal 2026 revenue guidance of $1,015–$1,035 million while raising adjusted operating margin guidance to 23.50%–24.00% and adjusted EPS guidance to $1.80–$1.90.
Embecta Corp. completed its acquisition of UK-based medical device maker Owen Mumford Holdings Limited on May 15, 2026. The deal includes an upfront cash payment of £126.0 million ($166.1 million), including £26.0 million of closing net cash, plus up to £50.0 million ($65.9 million) in performance-based earn-out payments tied to Aidaptus auto-injector net sales, for total potential consideration of £176.0 million ($232.0 million).
The amendment provides Owen Mumford’s audited fiscal 2025 financials and combined pro forma information. For the year ended September 30 2025, Owen Mumford generated turnover of £68.6 million, gross profit of £33.1 million and profit for the year of £1.68 million, with total comprehensive income of £1.32 million and net assets of £102.7 million. Cash at year-end was £29.6 million and operating cash flow was £6.0 million.
The auditor issued a qualified opinion solely because the special-purpose financial statements omit comparative prior-year information required under UK standards, while noting they otherwise present fairly under FRS 102. Pro forma results show combined revenues of $1,172.5 million and net income of $75.7 million for fiscal 2025, and $526.5 million of revenue and $32.5 million of net income for the six months ended March 31 2026, after reflecting purchase accounting, earn-out liabilities and financing effects.
Embecta Corp. has completed its previously announced acquisition of UK-based medical device maker Owen Mumford Holdings Limited. Embecta paid an upfront cash amount of £100 million at closing and may pay up to an additional £50 million if commercial milestones tied to net sales of the Aidaptus® next-generation auto-injector platform are achieved through June 30, 2029.
The deal is intended to accelerate Embecta’s shift from a pure insulin-delivery heritage into a broader medical supplies and drug-delivery platforms business. Owen Mumford adds a portfolio of chronic care and point-of-care devices, strong intellectual property, and device design, molding and assembly capabilities that can be combined with Embecta’s global commercial network and large-scale manufacturing to pursue opportunities across obesity, diabetes, autoimmune diseases and anaphylaxis.
Embecta reported weak second quarter fiscal 2026 results and cut its full-year outlook. Q2 revenues were $221.8 million, down 14.4%, with U.S. revenue falling 29.4% and international revenue up slightly on a reported basis. Gross margin declined to 57.6%, and the company posted a net loss of $4.1 million, or $(0.07) per diluted share, versus net income of $23.5 million and $0.40 a year earlier. Adjusted EPS was $0.27, down from $0.70.
For the first six months, revenue was $483.0 million, down 7.3%, with net income of $40.0 million and adjusted EPS of $0.98. Embecta now guides fiscal 2026 revenue to $1,015–$1,035 million and adjusted EPS to $1.55–$1.75, both sharply lower than prior guidance. The updated outlook assumes ongoing U.S. headwinds and includes the pending Owen Mumford acquisition, expected to add about $30 million of revenue and reduce adjusted EPS by roughly $0.15.
The board authorized a three-year $100 million share repurchase program and cut the quarterly dividend from $0.15 to $0.01 per share, reallocating cash toward repurchases and debt reduction. Management still expects to repay about $150 million of debt in 2026. As of March 31, 2026, the company held $193.4 million in cash and equivalents and restricted cash and had $1.342 billion of debt principal outstanding, with no borrowings on its $500 million revolver.
Embecta Corp. has agreed to acquire UK-based medical device maker Owen Mumford Holdings Limited in a transaction valued at up to £150 million. Embecta will pay £100 million in cash at closing, plus up to £50 million in additional payments tied to net sales of the Aidaptus® auto-injector platform through the three-year period following closing.
Owen Mumford generated net revenue of £69.4 million during its fiscal year 2025 and brings a portfolio of drug-delivery and chronic care devices that complement Embecta’s diabetes-focused franchise. Embecta expects the deal to support revenue growth from fiscal year 2027 onward, be accretive to adjusted operating income after fiscal year 2027, and generate a high-single-digit return on invested capital by year four.
The transaction, unanimously approved by Embecta’s board, is structured as a share acquisition for 100% of Owen Mumford’s equity and is expected to close in Embecta’s fiscal third quarter of 2026, subject to regulatory approvals and customary conditions. Embecta plans to fund the upfront purchase price with borrowings under its revolving credit facility.
Embecta Corp. reported the results of its 2026 Annual Meeting of Stockholders. All seven board nominees were elected to one-year terms, each receiving more than 45 million votes in favor, with several directors exceeding 48 million "For" votes.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026 with 53,083,728 votes in favor. On an advisory basis, stockholders approved executive compensation, and they approved an amendment to the 2022 Employee and Director Equity-Based Compensation Plan with 41,396,703 votes for and 7,034,781 against.
Embecta Corp. filed a current report to note that it released its financial results for the quarter ended December 31, 2025. The company issued a press release on February 5, 2026, and attached it as Exhibit 99.1, making the detailed quarterly results available to investors.
Embecta Corp. (EMBC) announced that it has released its financial results for the quarter and fiscal year ended September 30, 2025. The company reported these results in a press release dated November 25, 2025, which is included as an exhibit to the current report. This filing mainly serves to formally notify investors that the earnings information is available and to make the related press release part of the company’s public disclosures.
Embecta Corp. reported board leadership changes and one immediate director resignation. On November 17, 2025, director David A. Albritton resigned from the board and its Corporate Governance and Nominating Committee and Technology, Quality and Regulatory Committee for personal reasons, effective immediately, and the board size was reduced from nine to eight members. The company stated his resignation was not due to any disagreement with its operations, policies or practices. Also on November 17, 2025, Non-Executive Chairman LTG (Ret.) David F. Melcher informed Embecta he will not stand for re-election at the 2026 annual meeting, also not due to any disagreement. The independent directors expect to appoint CEO Devdatt (Dev) Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective upon Melcher’s departure.
Embecta Corp. furnished a press release announcing results for the quarter ended June 30, 2025. The company submitted an 8-K to share this update and included the full press release as Exhibit 99.1. The filing notes the update relates to results of operations and financial condition. Shares trade on Nasdaq under EMBC.